Company news
Knight Therapeutics, Inc. (TSX:GUD) news
Knight Therapeutics, Inc. news releases on 6ix. Latest, Oct 6, 2026: Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
Press releases & updates
Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil
October 6, 2026
Knight Therapeutics Announces Launch of TAVALISSE® in Brazil
October 6, 2026
Knight Therapeutics Enters into Exclusive Distribution Agreement with Kyowa Kirin International for Poteligeo® (Mogamulizumab)
September 29, 2026
Knight Therapeutics Inc. places No. 345 on The Globe and Mail’s eighth annual ranking of Canada's Top Growing Companies
September 25, 2026
Knight Therapeutics Announces Regulatory Submission of GEMTESA® in Canada
September 15, 2026
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Colombia
September 1, 2026
Knight Therapeutics Announces Supplemental Regulatory Submission for MINJUVI® (tafasitamab) in Brazil
August 27, 2026
Knight Therapeutics Announces Launch of WYNZORA® in Canada
August 20, 2026
Knight Therapeutics Reports Second Quarter 2026 Results
August 6, 2026
Notice of Knight Therapeutics' Second Quarter 2026 Results Conference Call
July 30, 2026
Knight Therapeutics Announces Repayment of Revolving Credit Facility
June 17, 2026
Knight Announces Early Warning Filing Regarding Shares of Crescita
June 5, 2026
Knight to Present at the Jefferies 2026 Healthcare Conference in New York City
May 28, 2026
Knight Therapeutics Announces Launch of TAVALISSE® in Mexico
May 27, 2026
Knight to Present at the 2026 RBC Capital Markets Global Healthcare Conference in New York City
May 12, 2026
Knight Therapeutics Announces Regulatory Approval of TAVALISSE® in Brazil
May 8, 2026
Knight Therapeutics Reports First Quarter 2026 Results
May 7, 2026
Notice of Knight Therapeutics' First Quarter 2026 Results Conference Call
April 30, 2026
Knight to Present at the 2026 Bloom Burton & Co. Healthcare Investor Conference
April 15, 2026
Knight Therapeutics Inc. ranks on The Globe and Mail's second annual Canada's Top Growing Women-Led Companies and seventh annual Women Lead Here benchmark of executive gender diversity
March 27, 2026
Knight Amends Normal Course Issuer Bid
March 23, 2026
Knight Therapeutics Reports Fourth Quarter and Year-End 2025 Results
March 19, 2026
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
March 17, 2026
Knight Therapeutics Announces Regulatory Supplemental Submission of MINJUVI® (tafasitamab) for Follicular Lymphoma in Argentina and Mexico
March 17, 2026
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
March 17, 2026
Knight Therapeutics Announces Approval of Additional Indication for MINJUVI® (tafasitamab) in Brazil
March 17, 2026
Notice of Knight Therapeutics' Fourth Quarter and Year End 2025 Results Conference Call
March 12, 2026
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil
February 18, 2026
Knight Therapeutics Announces Regulatory Submission of NIKTIMVO® (Axatilimab) in Brazil
February 18, 2026
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
December 18, 2025
Knight Therapeutics Announces Health Canada Approval for WYNZORA® to Treat Psoriasis Vulgaris
December 18, 2025
Profound Medical Regains Exclusive Distribution Rights for TULSA-PRO® in Canada from Knight
November 10, 2025
Knight Therapeutics Reports Third Quarter 2025 Results
November 6, 2025
Knight Announces Closing of US$100 Million Revolving Credit Facility
October 31, 2025
Knight Therapeutics Announces Launch of JORNAY PM(TM) in Canada
October 30, 2025
Knight Therapeutics Announces Launch of JORNAY PM™ in Canada
October 30, 2025
Notice of Knight Therapeutics' Third Quarter 2025 Results Conference Call
October 30, 2025
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
October 30, 2025
Knight Therapeutics Announces Approval and Launch of MINJUVI® (tafasitamab) in Argentina
October 30, 2025
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada
October 7, 2025
Knight Therapeutics Announces Relaunch of ORGOVYX® in Canada
October 7, 2025
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
October 7, 2025
Knight Therapeutics Announces Relaunch of MYFEMBREE® in Canada
October 7, 2025
Knight Therapeutics Inc. places No. 384 on The Globe and Mail's seventh annual ranking of Canada's Top Growing Companies
September 26, 2025
Knight Announces Normal Course Issuer Bid
August 20, 2025
Knight Therapeutics Reports Second Quarter 2025 Results
August 7, 2025
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
August 5, 2025
Knight Therapeutics Announces Regulatory Submission of CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Mexico
August 5, 2025
Knight Therapeutics and Incyte Amend Supply and Distribution Agreement to Add Retifanlimab and Axatilimab in Latin America
August 4, 2025
Notice of Knight Therapeutics' Second Quarter 2025 Results Conference Call
August 1, 2025